EU and US could reach trade deal this weekend - Reuters
Michael Burkes, the Chief Financial Officer of Natera, Inc. (NASDAQ:NTRA), recently executed a series of stock transactions, as reported in a recent SEC filing. On March 31, Burkes sold a total of 2,562 shares of Natera’s common stock, generating approximately $354,603. The shares were sold at prices ranging from $138.36 to $138.4101. The transaction comes as Natera, now valued at $19.08 billion, has delivered an impressive 53% return over the past year, according to InvestingPro data.
Earlier, on March 28, Burkes acquired 6,250 shares of common stock through the vesting of Restricted Stock Units (RSUs), which did not involve any monetary transaction. This acquisition brought his total holdings to 78,119 shares before the subsequent sales. InvestingPro analysis reveals that Natera maintains strong financial health with robust revenue growth of 56.75% in the last twelve months. Subscribers can access 11 additional ProTips and a comprehensive Pro Research Report for deeper insights.
The sale was conducted to cover tax obligations linked to the vesting of RSUs, aligning with a pre-established trading plan under Rule 10b5-1(c) of the Exchange Act.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, exceeding Wall Street expectations with revenue reaching $476 million, a 53% increase from the previous year, and a narrower-than-anticipated loss per share. The company’s gross margins improved significantly to 63%, up from 51% the previous year, indicating efficient cost management. Analysts at TD Cowen and Canaccord Genuity expressed optimism about Natera’s future, maintaining a Buy rating and increasing their price target to $195, citing strong sales guidance and potential benefits from improved Medicare Advantage rates. Natera has also launched the HEROES clinical trial to explore the potential for reducing therapy in metastatic HER2+ breast cancer patients, funded by the French Ministry of Health. This trial aims to understand the feasibility of ctDNA-guided treatment de-escalation in patients without detectable molecular disease. Recent developments also include the positive reception of Natera’s colorectal cancer study, which was positively received by analysts. These advancements are part of Natera’s ongoing efforts to expand its product offerings and improve patient care in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.